top of page
検索

FDA grants accelerated approval to Inovio Voceryq as first US plasmid DNA-based immunotherapy

執筆者の写真: nuaxia
nuaxia
11月2日
読了時間: 2分

The FDA has granted accelerated approval to Inovio's Voceryq, marking the first US authorisation of a plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis.


Voceryq is designed to reduce the frequency of surgical papilloma removal in adults with HPV-associated recurrent respiratory papillomatosis and is administered using Inovio's CELLECTRA 5PSP electroporation device.


In the RRP-001 study, 7 of 26 efficacy-evaluable patients, approximately 27%, required no surgery during 12 months of follow-up, while continued marketing authorisation remains dependent on confirmatory evidence under the FDA's accelerated approval pathway.

Field

Content

Article Type

Approvals

Company

Inovio Pharmaceuticals

Product

Voceryq

Modality

Plasmid DNA-based immunotherapy

Regulator

U.S. Food and Drug Administration

Approval Type

Accelerated approval

Approval Date

30 October 2026

Regulatory Milestone

First plasmid DNA-based immunotherapy approved in the United States

Indication

Recurrent respiratory papillomatosis in adults

Disease Cause

Human papillomavirus infection

Patient Population

Adults with recurrent respiratory papillomatosis

Treatment Objective

Reduce the frequency of surgical papilloma excisions

Administration Technology

CELLECTRA 5PSP electroporation device

Clinical Study

RRP-001

Efficacy-Evaluable Population

26 patients

Surgery-Free Patients

7 of 26 patients

Reported Surgery-Free Proportion

Approximately 27%

Reported Follow-Up

12 months

Regulatory Condition

Continued approval contingent on confirmatory evidence

Geographic Scope

United States

What Happened

The FDA granted accelerated approval to Voceryq for adults with recurrent respiratory papillomatosis.

Why It Matters

The decision introduces the first FDA-approved plasmid DNA-based immunotherapy and a treatment approach intended to reduce repeated surgical interventions.

Clinical Evidence

In RRP-001, seven of 26 efficacy-evaluable patients required no surgery during 12 months of follow-up.

Key Takeaway

Voceryq establishes a new therapeutic modality in US regulatory practice, although confirmatory evidence remains necessary.

What to Watch

Confirmatory clinical evidence, treatment adoption, durability of reduced surgical burden and post-approval safety monitoring.

Primary Source

U.S. Food and Drug Administration

Primary Source URL

https://www.fda.gov/news-events/press-announcements/fda-approves-first-plasmid-dna-based-immunotherapy-adults-recurrent-respiratory-papillomatosis

Relevant Date

30 October 2026


Discover how nuaxia can support your next medical education initiative:

 
 
 

コメント

5つ星のうち0と評価されています。
まだ評価がありません

評価を追加
bottom of page